Categories: medicin

  • Europa-Kommissionen godkender Teysuno til metastatisk tyktarmskræft

    26. januar 2022
    Europa-Kommissionen godkender Teysuno til metastatisk tyktarmskræft
    Nordic Pharma har annonceret, at Europa-Kommissionen den 24. januar godkendte den nye indikation for Teysuno® (tegafur/gimeracil/oteracil) til behandling af patienter med metastatisk tyktarmskræft, der ikke kan fortsætte behandling med fluoropyrimidiner på grund af særlige toksiciteter: hånd- og fodsyndrom

Enter your email address to follow Nordic Drugs

When you choose to create a user account and follow a newsroom your personal data will be used by us and the owner of the newsroom, for you to receive news and updates according to your subscription settings.

To learn more about this, please read our Privacy Policy, which applies to our use of your personal data, and our Privacy Policy for Contacts, which applies to the use of your personal data by the owner of the newsroom you follow.

Please note that our Terms of Use apply to all use of our services.

You can withdraw your consent at any time by unsubscribing or deleting your account.
Check your inbox

Email sent to __email__. Click the link there to follow Nordic Drugs.

Okay